GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (WBO:BMRN) » Definitions » Price-to-Free-Cash-Flow

Biomarin Pharmaceutical (WBO:BMRN) Price-to-Free-Cash-Flow

: 328.31 (As of Today)
View and export this data going back to 2017. Start your Free Trial

As of today (2024-04-23), Biomarin Pharmaceutical's share price is €83.72. Biomarin Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.26. Hence, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow Ratio for today is 328.31.

The historical rank and industry rank for Biomarin Pharmaceutical's Price-to-Free-Cash-Flow or its related term are showing as below:

WBO:BMRN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 75.6   Med: 358.71   Max: 711.43
Current: 327.95

During the past 13 years, Biomarin Pharmaceutical's highest Price-to-Free-Cash-Flow Ratio was 711.43. The lowest was 75.60. And the median was 358.71.

WBO:BMRN's Price-to-Free-Cash-Flow is ranked worse than
91.04% of 212 companies
in the Biotechnology industry
Industry Median: 30.29 vs WBO:BMRN: 327.95

Biomarin Pharmaceutical's Free Cash Flow per Share for the three months ended in Dec. 2023 was €-0.05. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was €0.26.

During the past 12 months, the average Free Cash Flow per Share Growth Rate of Biomarin Pharmaceutical was 14.90% per year.

During the past 13 years, Biomarin Pharmaceutical's highest 3-Year average Free Cash Flow per Share Growth Rate was 71.50% per year. The lowest was -131.90% per year. And the median was 3.70% per year.


Biomarin Pharmaceutical Price-to-Free-Cash-Flow Historical Data

The historical data trend for Biomarin Pharmaceutical's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 87.22 440.38 357.11

Biomarin Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 440.38 694.57 372.02 542.82 357.11

Competitive Comparison

For the Biotechnology subindustry, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Price-to-Free-Cash-Flow falls into.



Biomarin Pharmaceutical Price-to-Free-Cash-Flow Calculation

Biomarin Pharmaceutical's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=83.72/0.255
=328.31

Biomarin Pharmaceutical's Share Price of today is €83.72.
Biomarin Pharmaceutical's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.26.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Biomarin Pharmaceutical  (WBO:BMRN) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Biomarin Pharmaceutical Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (WBO:BMRN) Business Description

Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (WBO:BMRN) Headlines

From GuruFocus